10093677Dementia biomarker detection using resonant Raman spectroscopy at point of needClosedCollaborative R&DInnovate UKCertain diseases lead to complex bio-chemical processes within the body result in minute but detectable disease-specific changes in the chemistry of certain bodily fluids (such as tears or blood). One can then use measurements on these changes to diagnose the disease or even characterise the efficacy of a given treatment. This is attractive, as such fluids are easy to obtain with minimal discomfort to the patient and subsequent diagnostics can, potentially, be rapid and of low cost. Increasingly prevalent neurodegenerative disorders such as Alzheimer's disease are such conditions, as they modulate the concentrations of proteins within suitably obtained sample fluids. Measurement of these 'bio-markers' can then be used to judge the efficacy of and optimise highly patient-specific therapies. The changes in bio-marker concentration is so small that extremely sensitive, expensive and specialist-operator diagnostic tools are required to measure them. This significantly reduces patient access to effective precision therapies to those organisations or front-line healthcare providers large enough to countenance such expensive diagnostic equipment. In this proposal, we seek to break this limitation by realising low-cost, autonomous and low-consumable bio-marker measurement instrumentation which capitalises on established links between protein biomarkers and the neurodegenerative disorders which cause them.